Physician profile
Silvan Omerovic
NPI 1356836738
$6,186.31
in general payments reported to CMS, 2019-2025
22 companies · $801 in 2025
The $801 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $161 · 2021: $315 · 2022: $2,041 · 2023: $1,116 · 2024: $1,349 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,265.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,350.13 | 2022-2024 | Corevalve Evolut R |
| Amgen INC. | $758.68 | 2020-2024 | Repatha |
| Boston Scientific Corporation | $651.34 | 2019-2025 | Watchman Access System, Baylis Medical Company Radiofrequency Puncture Generator, Avvigo Guidance System |
| Inari Medical, INC. | $532.13 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Shockwave Medical, INC | $426.02 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $286.35 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $284.28 | 2021-2024 | Camzyos, Cobenfy |
| Merck Sharp & Dohme LLC | $282.14 | 2019-2021 | |
| Abbott Laboratories | $278.06 | 2024 | Cardiomems, Optis |
| Astrazeneca Pharmaceuticals LP | $237.85 | 2021-2024 | Andexxa, Brilinta |
| Philips North America LLC | $172.48 | 2022-2023 | |
| Stryker Corporation | $154.08 | 2025 | Flowtriever |
| Penumbra, INC. | $141.22 | 2024 | Indigo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.98 | 2019-2023 | Jardiance |
| Terumo Medical Corporation | $102.93 | 2024-2025 | Angio-Seal, Metacross Otw, Glidewire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $98.79 | 2019 | |
| W. L. Gore & Associates, INC. | $94.94 | 2025 | Gore Cardioform Septal Occluder |
| Angiodynamics, INC. | $79.57 | 2022-2024 | Alphavac |
| Chiesi USA, INC. | $70.29 | 2024 | Kengreal |
| Alexion Pharmaceuticals, INC. | $35.17 | 2020 | |
| Novartis Pharmaceuticals Corporation | $32.12 | 2024 | |
| Teleflex LLC | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silvan Omerovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.